Need professional-grade analysis? Visit stockanalysis.com
$39.83M
N/A
14
N/A
Vivoryon Therapeutics NV (VVY) trades on Euronext Amsterdam in EUR. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at EUR1.34, up 0.37% from the previous close.
Over the past year, VVY has traded between a low of EUR1.29 and a high of EUR1.81. The stock has lost 24.9% over this period. It is currently 25.7% below its 52-week high.
Vivoryon Therapeutics NV has a market capitalization of $39.83M.
Vivoryon Therapeutics N.V. operates as a clinical stage biopharmaceutical company that focuses on research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company's lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer's disease. In addition, the company is developing a monoclonal antibody PBD-C06 is for N3pE-Abeta. Vivoryon Therapeutics N.V. has a collaboration agreement with Nordic Bioscience for the clinical development of PQ912 for Alzheimer's disease; and research collaboration with the Fraunhofer Institute for cell therapy and immunology, as well as a strategic regional licensing partnership with Simcere Pharmaceutical Group Ltd. to develop and commercialize medicines targeting the neurotoxic amyloid species N3pE (pGlu-Abeta) to treat Alzheimer's disease. The company was founded in 1997 and is based in Halle, Germany.
Side-by-side comparison against top Healthcare peers.